

April 12, 2022

Intratech Medical Shareholders Update – Q1 2022

Dear Shareholders,

I am happy to give you an update on our progress, closing the first quarter of 2022.

Clinical Study

As you all know, the focus of the company for 2022 is our first-in-human (FIH) study. Last year, we completed the preclinical phase with very promising results, and we hope to have successful first cases in our FIH study.

For that purpose, we are in the final stages of getting approvals in several medical centers in Israel and abroad. In Israel, we have received the approval of the Ministry of Health to conduct the study, with Shamir Medical Center (Asaf-Harofe) to be the first center approved. In addition, we expect to get approvals in 3 additional sites in **Israel** within the next month:

- HaEmek Medical center
- Wolfson Medical Center
- Hillel-Yafe Medical Center

Another site for which we expect to get approvals by the end of the month is the cardiology department at the [First Hospital of Nanjing](#) (FHN) in **China**, led by Prof. Chen Shaoliang – a world-renowned researcher in the field of cardiology, on top of his academic and practice duties.

Additionally, we expect to get approvals in 2 leading centers in Tbilisi, **Georgia**: [Jerarsi Clinic](#) and [Helsicore](#) (Israel-Georgia hospital).

On top of these sites, we have started the process in another site in Serbia, where we received all the necessary approvals besides the final one. Unfortunately, due to the COVID situation in the country, no clinical trials were commenced in 2021, and it is not clear whether they will initiate new studies in 2022.

I would like to thank Prof. Giora Weisz, our Chief Medical Officer for leading our preclinical and clinical activities.

Finance

The funds of the current round are expected to support the enrolment of at least 5 patients in the FIH study, and to have the company ready for the next stage – acquisition by a strategic player in the cardiovascular market or round A fundraising.

Management

I would like to thank XT High-Tech Venture Capital, one of the major shareholders of Intratech, for the vote of confidence, to transition me to the position of active Chairman of the Board, replacing Mr. Assif Stoffman. I would like to express my personal appreciation, and I am doing so also on behalf of the Board of Directors, to Assif for his longstanding support of Intratech as one of the early investors of the company.

Replacing me in the position of CEO is Mr. [Tsachi Donner](#). Tsachi has 20 years of proven experience in the medical and digital health industry and has served in numerous leadership roles within global corporations and start-up companies, including the Israeli Ministry of Health. Tsachi previously served as CEO of Implant B and Haskama MD and holds a BA in Business Administration and an MBA from Ben-Gurion University.

I want to thank all of you for the continued support in our efforts and for enabling us to reach these important milestones. Please feel free to contact me directly with any questions you may have.

I wish you all a happy and safe Passover holiday!

Sincerely yours,

Moshe Barel, CEO

Intratech Medical



moshe@intratechmedical.com